NL-OMON38511已完成不适用
A RANDOMIZED, SINGLE-CENTER, OPEN-LABEL, 5-WAY CROSSOVER, SINGLE-DOSE BIOAVAILABILITY/BIOEQUIVALENCE COMPARISON OF BRIVARACETAM ORAL TABLETS (10MG, 50MG, 75MG, AND 100MG) AND BRIVARACETAM INTRAVENOUS BOLUS INJECTION (100MG) IN HEALTHY VOLUNTEERS - Brivaracetam BA/BE study
CB Pharma0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy males and females
- •18-55 years, incl.
- •BMI 18.0-30.0 kg/m2 incl.
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, 3-WAY CROSSOVER STUDY TO COMPARE THE RATE AND EXTENT OF RIVASTIGMINE ABSORPTION FROM A 7 DAY RIVASTIGMINE TRANSDERMAL SYSTEM (7-DAY RTS) WITH AND WITHOUT OVERLAY WITH 24-HR EXELON® PATCH APPLIED DAILY FOR 7 DAYS IN HEALTHY MALE AND FEMALE SUBJECTS10012272dementiaNL-OMON38506oven Pharmaceuticals, Inc.18
已完成
1 期
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BRIVARACETAM INTRAVENOUS FORMULATION GIVEN AS A 2-MINUTE IV BOLUS INJECTION, A 15-MINUTE IV INFUSION, AND AN ORALLY-DOSED TABLET IN HEALTHY MALE JAPANESE SUBJECTSJPRN-jRCT2080223863CB Japan Co., Ltd.24
已完成
不适用
SINGLE CENTER, OPEN LABEL, RANDOMIZED TWO-WAY CROSSOVER STUDY OF THE EFFECT OF LACOSAMIDE 200MG TWICE DAILY ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN (25 MG) IN HEALTHY MALE VOLUNTEERSseizures (attacks)10039911EpilepsyNL-OMON37817CB Pharma16
已完成
3 期
A Single Centre, Randomized, Open Label, Single Arm, Non-Comparative, Phase III Clinical study to Evaluate the Efficacy, Safety and Tolerability of JODOACT Cream in patients with acute musculoskeletal pain.CTRI/2023/05/052581PUNARJAN AYURVEDA PRIVATE LIMITED60
尚未招募
4 期
Investigating the effect and safety of NEERI KFT on impaired kidney functions and as an adjuvant with Nephrotoxic drugsCTRI/2023/07/054728Aimil Pharmaceuticals (India) Ltd.